The Lupus Nephritis market is anticipated to show positive growth owing to factors such as increasing prevalence, strong pipeline activity, and the presence of multiple Large-Cap Pharma players. LAS VEGAS, June 6, 2022 /PRNewswire/ -- DelveInsight's
Lupus Nephritis Market Insights report proffers a detailed comprehension of the lupus nephritis market size by treatment, epidemiology, emerging therapies, lupus nephritis market share of the individual therapies, current and forecasted lupus nephritis market size from 2019 to 2032 segmented into 7MM (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan). Some of the salient features from the
7MM is expected to grow at a
CAGR of 8.4% during the study period 2019-2032.
Key companies currently working in the market include names such as
Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, Novartis, Novartis Pharmaceuticals, Hoffmann-La Roche, Janssen Research & Development, BeiGene, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Alexion Pharmaceuticals, Omeros Corporation, Corestem, Inc., Bristol-Myers Squibb, Boehringer Ingelheim, Apellis Pharmaceuticals, AstraZeneca, Kezar Life Sciences, Equillium, Eledon Pharmaceuticals, Resolve Therapeutics, and others. As per our estimates, the total lupus nephritis market size in the United States accounted for 2021, which is likely to rise during the study period.
For further information on market impact by therapies, download the lupus nephritis market sample @ Common lupus nephritis signs include hematuria, proteinuria, edema, and sudden weight gain. It is vital that patients with lupus have routine urine analysis with microscopy looking for protein, blood, and cellular casts. Lupus nephritis is primarily caused by the deposition of immune complexes. The size of the complexes determines the deposition location, which leads to differences in classification. There are five types of lupus nephritis. Treatment is based on the type of lupus nephritis, determined by the biopsy. Since symptoms and severity vary from person to person, treatments are individually tailored to meet a person's particular circumstances. According to DelveInsight's analysis, the
209k cases in 2021 that are anticipated to increase by 2032.
lupus nephritis market report offers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into- Learn more about the lupus nephritis population trends for the 7MM by downloading @ The lupus nephritis treatment landscape currently has some approved therapies, while the principal goal of the present treatment regimen is to normalize renal function or, at least, prevent the progressive loss of renal function. However, therapy differs depending on the pathologic lesion. The lupus nephritis treatment strategies briefly emphasize the maximal preservation of renal function and patient protection from long-term consequences, mainly end-stage renal disease (ESRD) requiring dialysis or renal transplantation. In general, the mainstays for addressing lupus nephritis are mainly dominated by AURORA Phase III study and the Talking about the emerging lupus nephritis treatment landscape, several companies, including Roche, a third-generation, first humanized and glycoengineered CD20-directed cytolytic antibody, which is in the Phase III stage of clinical development. AstraZeneca, an investigational, fully human monoclonal antibody Discover which therapy is expected to grab a substantial lupus nephritis market share by downloading the report snapshot @ To know about more pipeline therapies, check @
Factors responsible for the anticipated growth in the lupus nephritis market include the increasing prevalence of this disease assisted by organizational support and a promising pipeline constituting late-stage products that are
expecting their approval. Other additional factors are
extensive research and development,
surge in the number of clinical studies contributing to the lupus nephritis market growth. On the contrary, several aspects such as a
high cost of treatment, the
need for novel therapeutics as well as a
need for a targeted treatment regimen can all serve as potential lupus nephritis market drawbacks. Know which lupus nephritis therapy is expected to score the touchdown first @ Coverage: 7MM (The United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)
Key lupus nephritis companies: Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, Novartis, Novartis Pharmaceuticals, Hoffmann-La Roche, Janssen Research and Development, BeiGene, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Alexion Pharmaceuticals, Omeros Corporation, Corestem, Inc., Bristol-Myers Squibb, Boehringer Ingelheim, Apellis Pharmaceuticals, AstraZeneca, Kezar Life Sciences, Equillium, Eledon Pharmaceuticals, Resolve Therapeutics, and others Therapeutic assessment: lupus nephritis current marketed and emerging therapies Competitive intelligence analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Market Access and Reimbursement
For further information on Market Impact by Therapies @
Get in touch with our Business executive @
"Graft-versus-host disease (GvHD) Market Insights Report" offers comprehensive details of pathophysiology and various diagnostic approaches, treatment algorithms. The report also offers profiling of GvHD pipeline therapeutics, ongoing Graft versus host disease clinical trials, key cross competition, and key pharmaceuticals like Medac, MaaT Pharma, ElsaLys Biotech (Mediolanum Farmaceutici Spa), Syndax Pharmaceutical, Kadmon Corporation, AstraZeneca, Biogen, Amgen, Pfizer, Bristol-Myers Squibb, CTI BioPharma, Novartis, GlaxoSmithKline, and several others. "IgA NephropathyIgA Nephropathy (IgAN) – Epidemiology Forecast to 2030" report delivers an in-depth understanding of the disease, historical and forecasted IgA Nephropathy (IgAN) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Epstein–Barr Virus-associated Post-transplant Lymphoproliferative Disease – Market Insights, Epidemiology, and Market Forecast – 2030" report delivers an in-depth understanding of the Epstein–Barr virus-associated post-transplant lymphoproliferative disease, treatment algorithms, profiling of pipeline therapeutics, ongoing clinical trials, key cross competition, and key pharmaceuticals involved. Chronic Renal/Kidney Transplant Rejection Market
"IgA NephropathyIgA Nephropathy – Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the IgA Nephropathy pipeline landscape. It covers the pipeline drug profiles and key companies involved are Lichen Planus – Market Insights, Epidemiology, and Market Forecast – 2030" report delivers an in-depth understanding of the Lichen Planus, historical and forecasted epidemiology, current treatment practices, emerging drugs, and unmet medical needs.
Guillain–Barre Syndrome Market Chronic Inflammatory Demyelinating Polyradiculoneuropathy Market
Autoimmune Hepatitis Market Insights, Epidemiology, and Market Forecast – 2030" report delivers an in-depth understanding of Autoimmune Hepatitis, historical and forecasted epidemiology as well as current treatment practices, emerging drugs, and unmet medical needs. "Psoriatic Arthritis (PsA) – Market Insights, Epidemiology, and Market Forecast – 2030" report deliver an in-depth understanding of the historical and forecasted epidemiology profiling of pipeline therapeutics, and key pharmaceuticals involved like AbbVie, Amgen/Pfizer, Bristol-Myers Squibb, Janssen Biotech, Amgen, Eli Lilly and Company, Pfizer, UCB, Bristol-Myers Squibb, Sun Pharma Global FZE, and many others. Browse Through Our Blog Posts
Is antibody-mediated rejection a roadblock to organ transplantation?
DelveInsight is a leading business consultant and market research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Connect with us - LinkedIn
SOURCE DelveInsight Business Research, LLP